HUTCHMED closes KRAS-EGFR license to GSK outside China
Question
HUTCHMED closes KRAS-EGFR license to GSK outside China
Direct answer
The $110 million upfront payment and ex-China rights transfer shift near-term cash and pipeline optionality for HCM, while GSK takes development risk on HMPL-A830.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-21
- Published
- 2026-10-21
- Revision
- 1 · 2026-10-21
Cite as: Market Ontology, “HUTCHMED closes KRAS-EGFR license to GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/hutchmed-closes-kras-egfr-license-to-gsk-outside-china-9a9840
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| HCM | pipeline monetization via a $110 million upfront license payment | Up1-4w | HUTCHMED will receive $110 million upfront and GSK gets worldwide rights excluding Greater China and Taiwan. |
| GSK | pipeline expansion via ex-China rights to HMPL-A830 with development spend and milestone risk | Mixed1-4w | GSK subsidiary gains worldwide rights excluding Greater China and Taiwan for HMPL-A830. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
- 2026-10-21HUTCHMED closed a KRAS-EGFR license with GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closed KRAS-EGFR therapy license to GSK outside ChinaGSK HCM
- 2026-10-21GSK gains ex-China rights to HMPL-A830GSK
- 2026-10-21HUTCHMED closes KRAS-EGFR license to GSK outside ChinaGSK HCM
- 2026-10-21HUTCHMED closes KRAS-EGFR conjugate license to GSK outside ChinaGSK HCM
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung CancerAZN HCM+3.39%
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancerAZN HCM+3.39%
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung CancerAZN HCM+3.39%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.